Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle

被引:34
|
作者
Starzer, Angelika M. [1 ,2 ]
Preusser, Matthias [1 ,2 ]
Berghoff, Anna S. [1 ,2 ]
机构
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, Vienna, Austria
[2] Med Univ Vienna, Dept Med 1, Christian Doppler Lab Personalized Immunotherapy, Vienna, Austria
关键词
cancer-immunity cycle; immune checkpoint inhibitors; immune escape; immune resistance; PD-L1; solid cancer; CELL LUNG-CANCER; SYSTEMIC INFLAMMATORY RESPONSE; TUMOR-ASSOCIATED MACROPHAGES; T-CELLS; SURVIVAL; IMMUNOTHERAPY; PD-L1; IPILIMUMAB; COMBINATION; MULTICENTER;
D O I
10.1177/17588359221096219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities for various cancer types. However, despite the success in some entities, a significant fraction of patients does not respond to immune checkpoint inhibitors. A functioning cancer-immunity cycle is needed as the precondition for a clinically meaningful response to immune checkpoint inhibitors. It is assumed that only if each step of the cycle is activated and functioning properly, immune checkpoint inhibitors induce a meaningful immune response. However, an activated cancer-immunity cycle might not be present equally in each patient and cancer type. Ideally, treatment concepts should consider each single step of the cancer-immunity cycle and provide personalized treatment approaches, allowing the adaption to functioning and malfunctioning steps of the individual patient's specific cancer-immunity cycle. In the following review, we provide an overview of the single steps of the cancer-immunity cycle as well as the impact of malfunctioning steps on the generation of an effective tumor-specific immune response.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Complementing the Cancer-Immunity Cycle
    Pio, Ruben
    Ajona, Daniel
    Ortiz-Espinosa, Sergio
    Mantovani, Alberto
    Lambris, John D.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [2] Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle
    Yan, Wei
    Jiang, Shuai
    TRENDS IN CANCER, 2020, 6 (06): : 506 - 517
  • [3] Mechanisms of immune escape in the cancer immune cycle
    Tang, Sha
    Ning, Qian
    Yang, Ling
    Mo, Zhongcheng
    Tang, Shengsong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 86
  • [4] Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges
    Zhang, Xiaokun
    Wu, Ye
    Lin, Jiayi
    Lu, Shengxin
    Lu, Xinchen
    Cheng, Aoyu
    Chen, Hongzhuan
    Zhang, Weidong
    Luan, Xin
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (09) : 3818 - 3833
  • [5] Recapitulating the Cancer-Immunity Cycle on a Chip
    Lee, Yujin
    Min, Jaehong
    Kim, Solbin
    Park, Wooju
    Ko, Jihoon
    Jeon, Noo Li
    ADVANCED HEALTHCARE MATERIALS, 2025, 14 (01)
  • [6] Metabolic regulation of the cancer-immunity cycle
    Patterson, Luis F. Somarribas
    Vardhana, Santosha A.
    TRENDS IN IMMUNOLOGY, 2021, 42 (11) : 975 - 993
  • [7] Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer
    Von Rueden, Samantha K.
    Fan, Timothy M.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] The Cancer-Immunity Cycle in Multiple Myeloma
    Casey, Mika
    Nakamura, Kyohei
    IMMUNOTARGETS AND THERAPY, 2021, 10 : 247 - 260
  • [9] The cancer-immunity cycle: Indication, genotype, and immunotype
    Mellman, Ira
    Chen, Daniel S.
    Powles, Thomas
    Turley, Shannon J.
    IMMUNITY, 2023, 56 (10) : 2188 - 2205
  • [10] STING: a master regulator in the cancer-immunity cycle
    Yuanyuan Zhu
    Xiang An
    Xiao Zhang
    Yu Qiao
    Tongsen Zheng
    Xiaobo Li
    Molecular Cancer, 18